Details of the Drug

General Information of Drug (ID: DM2VJ1U)

Drug Name
PF-06730512
Indication
Disease Entry ICD 11 Status REF
Focal segmental glomerulosclerosis MF8Y Phase 2 [1]
Drug Type
Fusion protein
Cross-matching ID
TTD ID
D6TS7K

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Slit homolog 2 protein (SLIT2) TTDWK85 SLIT2_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03448692) A PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS). U.S.National Institutes of Health.
2 PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis. Kidney Int Rep. 2021 Apr 3;6(6):1629-1633.